Medicine and Health Sciences Commons^™

Immune Checkpoint Inhibitor Therapy For Advanced Cutaneous Squamous Cell Carcinoma In Australia: A Retrospective Real World Cohort Study, Luke S. Mclean, Annette M. Lim, Mathias Bressel, Jenny Lee, Rahul Ladwa, Alexander D. Guminski, Brett Hughes, Samantha Bowyer, Karen Briscoe, Samuel Harris, Craig Kukard, Rob Zielinski, Muhammad Alamgeer, Matteo Carlino, Jeremy Mo, John J. Park, Muhammad A. Khattak, Fiona Day, Danny Rischin

Research outputs 2022 to 2026

Objectives: To review the outcomes of immune checkpoint inhibitor (ICI) treatment of advanced cutaneous squamous cell carcinoma (CSCC) outside clinical trials. Study design: Retrospective observational study; review of patient records in fifteen Australian institutions. Setting, participants: All Australian adults with locally advanced or metastatic CSCC not amenable to curative surgery or radiotherapy treated with ICIs, 5 May 2017 – 23 May 2022, through a cemiplimab compassionate access scheme (Therapeutic Goods Administration Special Access Scheme) or who personally covered the cost of pembrolizumab prior to the start of the access scheme. Main outcome measures: Best overall response rate (ORR) according to …